Clinical Trials Sponsored by ViiV Healthcare

Total 4392 results

ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus
ViiV Healthcare
GlaxoSmithKline

Completed

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Infection, Human Immunodeficiency Virus

United States, Spain, France, United Kingdom, Chile, Brazil, Italy, Portugal
ViiV Healthcare
Pfizer

Completed

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

HIV-1
ViiV Healthcare
Shionogi

Completed

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Infections, Human Immunodeficiency Virus and Hepatitis

United States
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
ViiV Healthcare
GlaxoSmithKline

Completed

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)

HIV Infections

Netherlands, United States, Italy, Spain, United Kingdom, France, Germany, Australia, Switzerland, Belgium, Canada, Poland, Sweden
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 1)

HIV Infections

United States, Canada
ViiV Healthcare
Pfizer

Completed

Multicenter, Safety Study Of Maraviroc

Acquired Immunodeficiency Syndrome | HIV Infection

Brazil
ViiV Healthcare
GlaxoSmithKline

Completed

HIV Treatment and CVD Events

HIV Infection | Cardiovascular Disease | Acute Myocardial Infarction | Infection, Human Immunodeficiency Virus
ViiV Healthcare
Pfizer

Completed

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Healthy

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Portugal, Russian Federation, Mexico, Argentina, South Africa, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

HIV Infections

United States, Germany, Spain, France, Australia, Canada, Belgium, Netherlands, United Kingdom, Japan
ViiV Healthcare
Pfizer

Completed

Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM)

Human Immunodeficiency Virus

United States, Canada, Spain, Belgium, France, United Kingdom, Italy, Brazil, Puerto Rico, Germany, Greece
Epividian
ViiV Healthcare

Completed

Charlotte Retention in Care Study

HIV I Infection

United States
ViiV Healthcare
GlaxoSmithKline

Completed

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
PPD

Completed

A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

HIV Infections

China
ViiV Healthcare
GlaxoSmithKline

Completed

Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

HIV Infections | Infection, Human Immunodeficiency Virus

Mexico, Peru, Thailand, South Africa, Russian Federation, Argentina, Brazil
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
Pfizer

Active, not recruiting

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Human Immunodeficiency Virus

Spain, United States, Italy, South Africa, Brazil, Mexico, Portugal, Puerto Rico, Thailand
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada
ViiV Healthcare
GlaxoSmithKline

Completed

Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1

HIV Infections

Germany
ViiV Healthcare
Pfizer

Completed

Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

CCR5-tropic HIV-1 Infection
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study of Combined Oral Contraceptive Effects in Female Subjects

Infection, Human Immunodeficiency Virus
ViiV Healthcare
GlaxoSmithKline

Completed

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
Pfizer

Completed

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

HIV Coinfection

United States, Germany, Poland, Spain, Czechia, United Kingdom, Hungary, Puerto Rico, France
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection (SONNET)

Infection, Human Immunodeficiency Virus

United States, Canada, Italy, Belgium, Romania
ViiV Healthcare
GlaxoSmithKline

Completed

Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients

Infection, Human Immunodeficiency Virus
ViiV Healthcare
GlaxoSmithKline

Terminated

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Infection, Human Immunodeficiency Virus
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status

Infection, Human Immunodeficiency Virus | Fracture
ViiV Healthcare
GlaxoSmithKline

Completed

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) (ASSURE)

Infection, Human Immunodeficiency Virus

United States, Puerto Rico
Pfizer
ViiV Healthcare

Completed

A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061

HIV-1

Germany
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine (MERIT)

HIV-1

United States, Canada, United Kingdom, Netherlands, Argentina, Australia, Belgium, South Africa, Switzerland, Italy, Puerto Rico, Brazil, Mexico, Poland
ViiV Healthcare
Pfizer

Completed

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

AIDS

Belgium
ViiV Healthcare
Pfizer

Completed

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Healthy

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
ViiV Healthcare
Shionogi

Completed

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

Healthy Volunteer

United States
ViiV Healthcare
Pfizer

Withdrawn

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Hepatitis B | Hepatitis C, Chronic | Human Immunodeficiency Virus

United States, Canada, Poland
ViiV Healthcare
Pfizer

Completed

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

HIV Infections | Healthy

Singapore

Clinical Trials Sponsored by ViiV Healthcare

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations